Neuroprotectants in stroke therapy

Expert Opin Pharmacother. 2008 Apr;9(6):887-900. doi: 10.1517/14656566.9.6.887.


Background: Over the past 10 years clinical trials aimed at finding suitable neuroprotectants against the debilitating effects of stroke have met with no success. Identifying novel neuroprotectants that can reverse the effects of stroke is becoming a challenge to both clinicians and scientists.

Objectives: This review focused on the current status on the topic and highlights some of the neuroprotectants that are worth examining or re-examining further.

Methods: Recent findings on the subject have been included.

Conclusion: Many neuroprotectants that have worked in preclinical evaluations have been found to be ineffective in clinical trials. Nevertheless, some of them are still considered to be worth re-examining. Non-coding small RNAs (riboregulators) as novel therapeutic leads have also been introduced in this review.

Publication types

  • Review

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Clinical Trials as Topic
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Amino Acid Antagonists / therapeutic use
  • GABA Agonists / pharmacology
  • GABA Agonists / therapeutic use
  • Humans
  • Hypothermia, Induced
  • Ion Channel Gating
  • Ion Channels / agonists
  • Ion Channels / antagonists & inhibitors
  • Magnesium Compounds / pharmacology
  • Magnesium Compounds / therapeutic use
  • Narcotic Antagonists
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Nootropic Agents / pharmacology
  • Nootropic Agents / therapeutic use
  • Stroke / drug therapy*
  • Stroke / physiopathology
  • Stroke / therapy


  • Antioxidants
  • Excitatory Amino Acid Antagonists
  • GABA Agonists
  • Ion Channels
  • Magnesium Compounds
  • Narcotic Antagonists
  • Neuroprotective Agents
  • Nootropic Agents